• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Clinical pharmacology: current status and perspectives].

作者信息

De Schaepdryver A F

机构信息

J.F. & C. Heymans Instituut voor Farmacologie, Universiteit Gent.

出版信息

Verh K Acad Geneeskd Belg. 1992;54(1):7-26.

PMID:1636323
Abstract

In view of the ever increasing complexity of individualized pharmacotherapy, the study of new and potent drugs in man and the misuse and abuse of drugs, WHO-Study Group reports and a recent enquiry in Belgium, France and W. Germany stress that the development of clinical pharmacology is an absolute necessity for patients, physicians, health authorities, the pharmaceutical industry and society at large. It seems this development could be optimally achieved by setting up, within Services of General Medicine or Internal Medicine of University Hospitals and large Public Hospitals, autonomous Units of Clinical Pharmacology with the responsibility to take an active part: a) at the service level: 1) in patient care, either directly in general medical services or drug problem oriented consultations, or indirectly through consultative functions and pharmacotherapeutic conferences; 2) in drug monitoring services, management of cases of overdose, drug information, drug utilization surveys, pharmaco-epidemiology, ethical committees, formulary committees, drug regulatory agencies and studies of Phase I, II and III; b) at the teaching level: 1) in courses of clinical pharmacology sui generis, to undergraduates, in close collaboration with the University Department of Pharmacology; 2) at the postgraduate level, as a specialty in se, and as part of the training in medical specialties and at the level of continuing education of general practitioners and specialists; c) at the research level: 1) in clinical pharmacokinetic studies, with special attention to interindividual variability and genetic factors, to drug concentration/effect studies, to drug interactions, and in pharmacodynamic studies, in view of the development of new approaches in the study of drug-receptor interactions; 2) in the design, realization and evaluation of Phase I, II and III studies, clinical trials and multicenter drug studies.

摘要

相似文献

1
[Clinical pharmacology: current status and perspectives].
Verh K Acad Geneeskd Belg. 1992;54(1):7-26.
2
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
3
[Social pharmacology: a new topic in clinical pharmacology].[社会药理学:临床药理学中的一个新课题]
Therapie. 2002 Sep-Oct;57(5):420-6.
4
Lessons learned from independent central review.独立中央审查的经验教训。
Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.
5
How to anticipate the assessment of the public health benefit of new medicines?如何预测对新药公共卫生效益的评估?
Therapie. 2007 Sep-Oct;62(5):427-35. doi: 10.2515/therapie:2007071. Epub 2008 Jan 19.
6
[Current status and needs of the department of neurology as a specialized department of a general hospital].[综合医院神经内科作为专科科室的现状与需求]
Rinsho Shinkeigaku. 2000 Dec;40(12):1301-4.
7
[Difficulties with conducting clinical trials in France].[在法国开展临床试验的困难]
Therapie. 2001 Jul-Aug;56(4):341-7.
8
A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.一个就注意力缺陷/多动障碍的诊断和管理达成社区共识的过程。
Pediatrics. 2005 Jan;115(1):e97-104. doi: 10.1542/peds.2004-0953.
9
[Drug research in Germany--problems and chances--from the viewpoint of the drug industry].[德国的药物研究——问题与机遇——从制药行业的视角来看]
Arzneimittelforschung. 1998 Nov;48(11):1047-50.
10
[Principles and perspectives of clinical pharmacology].[临床药理学的原理与展望]
Klin Wochenschr. 1991;69 Suppl 26:8-12.